Atara Biotherapeutics ATA188 for MS
Atara Biotherapeutics (ATRA) announced the presentation of initial efficacy data as well as updated safety results from its ongoing Phase 1 study of the firm’s product ATA188 for the treatment of a progressive . . .
This content is for paid subscribers.
Today’s Highlights September 17, 2019